BEACON-IPF – BiotechReality – Information Intelligence System for Biopharma

The BEACON-IPF Phase 2b trial, which was assessing bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), has been discontinued by Pliant Therapeutics, Inc. after a predetermined data review and recommendation by the independent Data Safety Monitoring Board (DSMB) of the trial and a secondary review and recommendation by an external expert panel. Early evidence of benefit on the forced vital capacity (FVC) endpoint was also noted, although the trial was terminated due to an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups. The first late-stage IPF trial to be terminated for safety while having compelling efficacy data is BEACON-IPF. In BEACON-IPF, the average exposure time was almost 17 weeks. Overall, there were about 10% of IPF-related adverse events in both dosage groups, which is comparable. The low (less than 3%) occurrence of IPF-related adverse events in the placebo group seems to have been the primary cause of the imbalance between the active and placebo groups. In contrast, IPF-related adverse events were similar among persons treated with bexotegrast (7%) at all doses and placebo (10%) in the Phase 2a INTEGRIS-IPF trial (mean exposure period of roughly 16 weeks). Also Read: Combination of chemotherapy and dual-targeted treatments Phase III Breakwater Clinical trials supported for BRAF-mutated metastatic colorectal cancer FDA approval The company intends to assess the BEACON-IPF trial's full data and determine the best course of action for bexotegrast's development. The company will take into consideration more dose-ranging Phase 2b studies with lower doses in pulmonary fibrosis and possibly other non-respiratory indications, such as liver diseases, after the complete analysis is finished, which should give a better understanding of the benefit risk profile and therapeutic window of bexotegrast. Source: Pliant Therapeutics Last Modified:

Tag: BEACON-IPF

BEACON-IPF Clinical Trial for Idiopathic Pulmonary Fibrosis Discontinued With Available Results

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment